Claims
- 1. An isolated polypeptide selected from the group consisting of:
(a) a polypeptide having an amino acid sequence identical to a portion of the amino acid sequence of SEQ ID NO:2, wherein the amino terminus of said polypeptide is residue 4 of SEQ ID NO:2 and the carboxy terminus is residue m, wherein m is any residue from residue 48 to residue 93 of SEQ ID NO:2; and (b) a polypeptide having an amino acid sequence identical to that of (a), except for at least one amino acid substitution.
- 2. The polypeptide of claim 1, which is (a).
- 3. The polypeptide of claim 1, which is (b).
- 4. The polypeptide of claim 2, which is an antagonist of Chemokine β-6 (Ckβ-6).
- 5. The polypeptide of claim 3, which is an antagonist of Chemokine β-6 (Ckβ-6).
- 6. The polypeptide of claim 2, having the amino acid sequence Pro (4) to Arg (73) of SEQ ID NO:2.
- 7. The polypeptide of claim 2, with a Met residue at the N-terminus.
- 8. The polypeptide of claim 3, with a Met residue at the N-terminus.
- 9. The polypeptide of claim 6, with a Met residue at the N-terminus.
- 10. An isolated nucleic acid molecule encoding the polypeptide of claim 1.
- 11. A method for making a recombinant vector comprising inserting the nucleic acid molecule of claim 10 into a vector.
- 12. A recombinant vector produced by the method of claim 11.
- 13. A method of making a recombinant host cell comprising introducing the recombinant vector of claim 12 into a host cell.
- 14. A recombinant host cell produced by the method of claim 13.
- 15. A method for producing a polypeptide comprising culturing the host cell of claim 14 under conditions such that said polypeptide is expressed and recovering said polypeptide.
- 16. A method for treating diseases and disorders selected from the group consisting of: autoimmune diseases, inflammation, rheumatoid arthritis, atherosclerosis, allergies, dermatitis, chronic urticaria, adult respiratory distress syndrome, asthma, rhinitis, eczema and infectious diseases comprising:
administereing to a patient in need thereof an effective amount of the polypeptide of claim 1.
- 17. The method of claim 16, wherein said polypeptide inhibits activation or moblization of eosinophils.
- 18. The method of claim 16, wherein said polypeptide inhibits activation or moblization of basophils.
- 19. The method of claim 16, wherein said polypeptide binds Chemokine Receptor-3.
- 20. An isolated polypeptide selected from the group consisting of:
(a) a polypeptide having an amino acid sequence identical to a portion of the amino acid sequence of SEQ ID NO:2, wherein the amino terminus of said polypeptide is residue 2 of SEQ ID NO:2 and the carboxy terminus is residue m, wherein m is any residue from residue 48 to residue 93 of SEQ ID NO:2; and (b) a polypeptide having an amino acid sequence identical to a portion of the amino acid sequence of SEQ ID NO:2, wherein the amino terminus of said polypeptide is residue 3 of SEQ ID NO:2 and the carboxy terminus is residue m, wherein m is any residue from residue 48 to residue 93 of SEQ ID NO:2; and (c) a polypeptide having an amino acid sequence identical to a portion of the amino acid sequence of SEQ ID NO:2, wherein the amino terminus of said polypeptide is residue 1 of SEQ ID NO:2 and the carboxy terminus is residue m, wherein m is any residue from residue 48 to residue 92 of SEQ ID NO:2; (d) a polypeptide having an amino acid sequence identical to that of (a), except for at least one amino acid substitution; (e) a polypeptide having an amino acid sequence identical to that of (b), except for at least one amino acid substitution; and (f) a polypeptide having an amino acid sequence identical to that of (c), except for at least one amino acid substitution.
- 21. The isolated polypeptide of claim 20, which is (a).
- 22. The isolated polypeptide of claim 20, which is (b).
- 23. The isolated polypeptide of claim 20, which is (c).
- 24. The isolated polypeptide of claim 20, which is (d).
- 25. The isolated polypeptide of claim 20, which is (e).
- 26. The isolated polypeptide of claim 20, which is (f).
- 27. The isolated polypeptide of claim 20, which is an agonist of Ckβ-6.
- 28. The isolated polypeptide of claim 20, having an amino acid sequence of SEQ ID NO:2 selected from the group consisting of: Val (1) to Arg (73); Val (2) to Arg (73); Ile (3) to Arg (73); Val (1) to Arg (75); Val (1) to Ala (76); and Val (1) to Ala (78).
- 29. The polypeptide of claim 20, with a Met residue at the N-terminus.
- 30. The polypeptide of claim 28, with a Met residue at the N-terminus.
- 31. An isolated nucleic acid molecule encoding the polypeptide of claim 20.
- 32. A method for making a recombinant vector comprising inserting the nucleic acid molecule of claim 31 into a vector.
- 33. A recombinant vector produced by the method of claim 32.
- 34. A method of making a recombinant host cell comprising introducing the recombinant vector of claim 33 into a host cell.
- 35. A recombinant host cell produced by the method of claim 34.
- 36. A method for producing a polypeptide comprising culturing the host cell of claim 35 under conditions such that said polypeptide is expressed and recovering said polypeptide.
- 37. A method for activating or moblizing basophils or eosinophils comprising: administering to a patient in need therof an effective amound of the polpeptide of claim 20.
- 38. The method of claim 37, wherein said polypeptide is injected into said patient to increase local eosinophil or basophil infiltration.
- 39. The method of claim 37, wherein said polypeptide stimulates histamine release.
- 40. A method of myeloprotection comprising an effective amount of the polypeptide of claim 20 to a patient undergoing chemotherapy.
Parent Case Info
[0001] This application is a continuation of U.S. application Ser. No. 08/995,156, filed Dec. 19, 1997, presently allowed, which claims the benefit of U.S. Provisional Application No. 60/042,269, filed Mar. 31, 1997, both of which disclosures are herein incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60042269 |
Mar 1997 |
US |
Divisions (2)
|
Number |
Date |
Country |
Parent |
09419281 |
Oct 1999 |
US |
Child |
10054967 |
Jan 2002 |
US |
Parent |
08995156 |
Dec 1997 |
US |
Child |
09419281 |
Oct 1999 |
US |